Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate [Phase 1]

View source ↗

Summary

A Phase 1 trial update of tanespimycin (17-N-allylamino-17-demethoxygeldanamycin) in patients with chronic phase chronic myeloid leukemia resistant to imatinib …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Leukemia | Phase 1 | Status: COMPLETED